fda rules on compounded semaglutide 🚨 Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these The FDA's Decision to Ban

Document each dose, injection site, and timing to maintain consistency

Each improvement builds on the others, creating momentum toward better cardiovascular health

What This Means for Compounding Pharmacies For compounding pharmacies, the practical implications are significant: Legal clarity : Pharmacies no longer need to fear FDA enforcement action specifically for compounding these 12 peptides Inventory restoration : Pharmacies that removed these peptides from their formularies due to legal risk can restore them Quality improvements : As legitimate compounding channels reopen, the quality gap between regulated and gray-market sources should narrow Pricing normalization : As multiple compounding pharmacies compete, excessive premiums for "research use only" labeling should decline 503B outsourcing facilities which compound for hospitals and clinics will likely move faster than individual 503A pharmacies due to their larger scale and regulatory compliance infrastructure

eTable A lists resources supporting the diagnosis and management of hypermobility syndromes

How They Work Tirzepatide: This medication combines the actions of two incretin hormones, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)